Hdl Handle:
http://hdl.handle.net/10147/296529
Title:
Proteomic classification of breast cancer.
Authors:
Kamel, Dalia; Brady, Bernadette; Tabchy, Adel; Mills, Gordon B; Hennessy, Bryan
Affiliation:
Department of Medical Oncology, Our Lady of Lourdes Hospital, Drogheda, Ireland. dsskamel@hotmail.com
Citation:
Proteomic classification of breast cancer. 2012, 13 (12):1495-509 Curr Drug Targets
Journal:
Current drug targets
Issue Date:
Nov-2012
URI:
http://hdl.handle.net/10147/296529
PubMed ID:
22974393
Abstract:
Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme-linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
Item Type:
Article
Language:
en
MeSH:
Animals; Breast Neoplasms; Female; Humans; Individualized Medicine; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Proteomics; Tumor Markers, Biological
ISSN:
1873-5592

Full metadata record

DC FieldValue Language
dc.contributor.authorKamel, Daliaen_GB
dc.contributor.authorBrady, Bernadetteen_GB
dc.contributor.authorTabchy, Adelen_GB
dc.contributor.authorMills, Gordon Ben_GB
dc.contributor.authorHennessy, Bryanen_GB
dc.date.accessioned2013-07-19T11:01:59Z-
dc.date.available2013-07-19T11:01:59Z-
dc.date.issued2012-11-
dc.identifier.citationProteomic classification of breast cancer. 2012, 13 (12):1495-509 Curr Drug Targetsen_GB
dc.identifier.issn1873-5592-
dc.identifier.pmid22974393-
dc.identifier.urihttp://hdl.handle.net/10147/296529-
dc.description.abstractBeing a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme-linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Current drug targetsen_GB
dc.subject.meshAnimals-
dc.subject.meshBreast Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIndividualized Medicine-
dc.subject.meshNeoplasm Proteins-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshPrognosis-
dc.subject.meshProteomics-
dc.subject.meshTumor Markers, Biological-
dc.titleProteomic classification of breast cancer.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Our Lady of Lourdes Hospital, Drogheda, Ireland. dsskamel@hotmail.comen_GB
dc.identifier.journalCurrent drug targetsen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.